193 related articles for article (PubMed ID: 35245519)
1. Antitumor effects of rhamnazinon sorafenib-treated human hepatocellular carcinoma cell lines via modulation of VEGF signaling and PI3K/NF-κB p38/caspase-3 axes cross talk.
Habiba YH; Omran GA; Helmy MW; Houssen ME
Life Sci; 2022 May; 297():120443. PubMed ID: 35245519
[TBL] [Abstract][Full Text] [Related]
2. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
[TBL] [Abstract][Full Text] [Related]
3. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
4. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
5. A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
Xu YY; Chen L; Wang GL; Zhou JM; Zhang YX; Wei YZ; Zhu YY; Qin J
BMC Cancer; 2013 Nov; 13():527. PubMed ID: 24195809
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
7. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
9. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
10. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
11. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
12. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA
Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700
[TBL] [Abstract][Full Text] [Related]
13. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.
Taha AM; Aboulwafa MM; Zedan H; Helmy OM
Sci Rep; 2022 Oct; 12(1):17889. PubMed ID: 36284117
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Lu M; Fei Z; Zhang G
Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
[TBL] [Abstract][Full Text] [Related]
18. Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.
Yang H; Wang J; Fan JH; Zhang YQ; Zhao JX; Dai XJ; Liu Q; Shen YJ; Liu C; Sun WD; Sun Y
Toxicol Appl Pharmacol; 2017 Jan; 315():90-101. PubMed ID: 27986624
[TBL] [Abstract][Full Text] [Related]
19. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]